Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures

• Males or females (of non-child bearing potential) aged 18 to 55 years (inclusive)

• Minimum weight of 50 kg and a body mass index (BMI) of 18 to 35 kg/m2 (inclusive)

• Males must be willing to use barrier contraception ie, condoms, from the first administration until 2 weeks after the last administration of the investigational product

Exclusion Criteria:

• History or presence of gastrointestinal, hepatic or renal disease (except for cholecystectomy)

• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the investigational product

• Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day

• Absolute neutrophil count of less than 2500/mm3 or 2.5 x 109/L

• Any previous treatment with fostamatinib or pioglitazone